# A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

> **NCT06833073** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 308 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Carcinoma in Situ

## Interventions

- **BIOLOGICAL:** Intismeran autogene
- **BIOLOGICAL:** BCG

## Key facts

- **NCT ID:** NCT06833073
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2031-09-03
- **Final completion:** 2031-09-03
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06833073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06833073, "A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06833073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*